Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study
Celcuity Inc. presented updated clinical data from the PIK3CA mutation cohort of its Phase 3 VIKTORIA-1 study at the ESMO Congress 2026.
Stocks · News reference
Celcuity Schedules Release of Third Quarter 2026 Financial Results
Celcuity Inc. announced it will release its financial results for the third quarter of 2026 after the market closes on November 5, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Celcuity Announces Updated Clinical Results for Gedatolisib in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc. presented updated Phase 1b/2 clinical trial data for its lead therapeutic candidate, gedatolisib, at the 2026 ESMO Congress, showing promising progression-free survival rates in patients with metastatic castration-resistant prostate cancer.
Cantor Fitzgerald Initiates Celcuity at Overweight With $140 Price Target
Cantor Fitzgerald has initiated coverage on Celcuity Inc. with an Overweight rating and a price target of $140.